Nemaura Medical Provides Update Regarding Commercial Launch of SugarBEAT® and First Patient User Experiences as Presented at...
October 03 2019 - 9:00AM
Nemaura Medical, Inc. (NASDAQ: NMRD)
(“Nemaura”), a medical technology company focused on the
commercialization of SugarBEAT® as a non-invasive, affordable and
flexible Continuous Glucose Monitor (CGM) for use by diabetics and
pre-diabetics, today provided an update regarding the commercial
launch of SugarBEAT® and feedback from its first patient user
experiences as presented at the recent symposia hosted by Nemaura
at the 55th Annual Meeting of the European Association for
the Study of Diabetes (EASD) in Barcelona.
Dr. Faz Chowdhury, Chief Executive Officer, discussed key
milestones in the development and plans for the commercial rollout
program for SugarBEAT® in the UK, Ireland, Germany and other key
European markets following its recent CE mark approval in the
European Union.
Dr. Fred Schaebsdau, VP Strategic Alliances, highlighted key
competitive advantages of SugarBEAT® over current invasive CGM
technologies. SugarBEAT® represents the world’s first non-invasive,
safe, needle-free, CGM as it does not puncture the skin to insert a
sensor and allows users the freedom to decide when, and for how
long to wear the patch. Dr. Schaebsdau also discussed the positive
first user experiences indicating that SugarBEAT® can be an
effective tool for early diagnosis of type 2 diabetes, therapy
optimization, prevention, improvement and lifestyle change.
Dr. Iain Cranston, a diabetes specialist based in the UK at
Portsmouth Hospital NHS Trust presented prior clinical data
confirming that the SugarBEAT® is uniquely positioned to target the
Type 2 diabetes and pre-diabetic markets, as well as health
conscious individuals that can expect early benefits with the
treatment by adopting self-management programs.
Dr. Faz Chowdhury, CEO of Nemaura commented, “With our current
scale of manufacturing in United Kingdom and the first shipments of
SugarBEAT® CGM devices to diabetic and pre-diabetic patients, we
believe we are well positioned to move aggressively into the
commercial phase of our strategy in Europe. We have established
strategic partnerships in the United Kingdom and Ireland to
commence sales and distribution, and are diligently working with
our partners to develop the launch plan and various subscription
options.”
“We are very pleased to report positive first user experiences
at this premier industry conference. Importantly, as a daily
disposable adhesive skin-patch that sits on the surface of the
skin, SugarBEAT® is painless, and versatile in terms of wear time.
Given these benefits, we look forward to aggressively entering the
underserved markets for both Type 2 diabetics and pre-diabetics,
which are estimated at $80 billion per year.”
Nemaura’s presentations from the European Association for the
Study of Diabetes (EASD) symposia in Barcelona on September 19,
2019 are available at the Company’s website:
https://nemauramedical.com/easd-symposia-2019/
About Nemaura Medical, Inc.:
Nemaura Medical, Inc. (NASDAQ: NMRD), is a
medical technology company commercializing SugarBEAT® as a
non-invasive, affordable and flexible Continuous Glucose Monitor
(CGM) designed to help people with diabetes and pre-diabetics
better manage their glucose levels by spending more time in range.
Insulin users can adjunctively use SugarBEAT® when calibrated
by a finger stick reading. SugarBEAT® consists of a daily,
disposable adhesive skin-patch connected to a small form factor
rechargeable transmitter, connected via Bluetooth to a specially
designed mobile application, which displays glucose readings at
five-minute intervals throughout the day.
For more information visit:
www.NemauraMedical.com
www.SugarBEAT.com
Cautionary Statement Regarding Forward-Looking
Statements:
The statements in this press release that are
not historical facts, and may constitute forward-looking statements
that are based on current expectations and are subject to risks and
uncertainties that could cause actual future results to differ
materially from those expressed or implied by such statements.
Those risks and uncertainties include, but are not limited to,
risks related to regulatory approvals and the success of Nemaura’s
ongoing studies, including the safety and efficacy of Nemaura’s
SugarBEAT® system, the failure of future development and
preliminary marketing efforts, Nemaura’s ability to secure
additional commercial partnering arrangements, risks and
uncertainties relating to Nemaura and its partners’ ability to
develop, market and sell SugarBEAT®, the availability of
substantial additional equity or debt capital to support its
research, development and product commercialization activities, and
the success of its research, development, regulatory approval,
marketing and distribution plans and strategies, including those
plans and strategies related to SugarBEAT®. These and other risks
and uncertainties are identified and described in more detail in
Nemaura’s filings with the United States Securities and Exchange
Commission, including, without limitation, its Annual Report on
Form 10-K for the most recently completed fiscal year, its
Quarterly Reports on Form 10-Q, and its Current Reports on Form
8-K. Nemaura undertakes no obligation to publicly update or revise
any forward-looking statements.
Contact:
Crescendo Communications, LLC 212-671-1021
NMRD@crescendo-ir.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Apr 2023 to Apr 2024